| Variables . | Total . | Non-ablation centres ( n = 23) . | Ablation centres ( n = 20) . | P . |
|---|---|---|---|---|
| Patient number, total | 1256 | 584 | 672 | |
| Outpatients | 694 (55.3%) | 300 (51.4%) | 394 (58.6%) | 0.323 |
| Age, years | 68 ± 12 | 69 ± 12 | 66 ± 11 | <0.01 |
| Males | 672 (53.5%) | 338 (57.9%) | 424 (63.1%) | 0.058 |
| Ejection fraction, % | 54 ± 10 | 54 ± 9 | 54 ± 10 | 0.793 |
| Left atrium diameter, mm | 4.6 ± 0.7 | 4.6 ± 0.7 | 4.6 ± 0.8 | 0.6 |
| Hypertension | 487 (38%) | 246 (42%) | 241 (36%) | <0.01 |
| Structural heart disease | 468 (37%) | 226 (38%) | 242 (36%) | 0.113 |
| Ischaemic | 147 | 82 | 65 | 0.07 |
| Hypertensive | 37 | 19 | 18 | 0.811 |
| Dilated | 96 | 34 | 62 | <0.01 |
| Valvular | 151 | 79 | 72 | 0.37 |
| Other | 37 | 12 | 25 | 0.05 |
| New-onset AF | 297 (23.6%) | 174 (29.8%) | 123 (18.3%) | 0.047 |
| Idiopathic AF | 301 (24%) | 110 (18.8%) | 191 (28.4%) | 0.039 |
| Paroxysmal AF | 417 (33%) | 152 (26%) | 265 (39%) | 0.03 |
| Persistent AF | 677 (54%) | 333 (57%) | 344 (51%) | <0.001 |
| Long-lasting persistent/permanent | 162 (13%) | 99 (17%) | 63 (10%) | <0.001 |
| Duration of AF (years) | 2 (0–5) | 1 (0–4) | 3 (1–5) | 0.01 |
| Number of arrhythmic episodes during the last year | 1 (1–3) | 1 (1–2) | 1 (1–4) | <0.01 |
| Number of hospitalizations for AF during the last year | 0 (0–1) | 1 (0–1) | 1 (1–2) | 0.252 |
| Number of antiarrhythmic drugs | 1 (0–2) | 1 (0–1) | 1 (1–2) | <0.01 |
| Amiodarone | 467 (37.2%) | 193 (33%) | 274 (40.8%) | 0.189 |
| SSS: brady–tachy form | 108 (8.5%) | 69 (11.8%) | 39 (5.8%) | 0.06 |
| Cardiac pacing | 134 (10.7%) | 68 (11.6%) | 66 (9.8%) | 0.741 |
| Previous catheter ablation | 116 (9.2%) | 24 (4.1%) | 92 (13.7%) | <0.01 |
| Thrombo-embolic risk ≥1 | 1053 (83.8%) | 502 (86%) | 551(82%) | 0.210 |
| OAT contraindications | 36 (2.9%) | 20 (3.4%) | 16 (2.4%) | 0.268 |
| Symptoms correlated to AF | 914 (72.8%) | 384 (65.8%) | 530 (78.9%) | 0.006 |
| Significant symptom | 654 (52.1%) | 244 (41.8%) | 410 (61%) | 0.01 |
| QoL impairment | 406 (32.3%) | 159 (27.2%) | 247 (36.8%) | 0.232 |
| EF deterioration due to AF | 144 (11.5%) | 74 (12.7%) | 70 (10.4%) | 0.373 |
| Refractoriness to medical therapy | 492 (39.2%) | 136 (23.3%) | 356 (53%) | <0.01 |
| Variables . | Total . | Non-ablation centres ( n = 23) . | Ablation centres ( n = 20) . | P . |
|---|---|---|---|---|
| Patient number, total | 1256 | 584 | 672 | |
| Outpatients | 694 (55.3%) | 300 (51.4%) | 394 (58.6%) | 0.323 |
| Age, years | 68 ± 12 | 69 ± 12 | 66 ± 11 | <0.01 |
| Males | 672 (53.5%) | 338 (57.9%) | 424 (63.1%) | 0.058 |
| Ejection fraction, % | 54 ± 10 | 54 ± 9 | 54 ± 10 | 0.793 |
| Left atrium diameter, mm | 4.6 ± 0.7 | 4.6 ± 0.7 | 4.6 ± 0.8 | 0.6 |
| Hypertension | 487 (38%) | 246 (42%) | 241 (36%) | <0.01 |
| Structural heart disease | 468 (37%) | 226 (38%) | 242 (36%) | 0.113 |
| Ischaemic | 147 | 82 | 65 | 0.07 |
| Hypertensive | 37 | 19 | 18 | 0.811 |
| Dilated | 96 | 34 | 62 | <0.01 |
| Valvular | 151 | 79 | 72 | 0.37 |
| Other | 37 | 12 | 25 | 0.05 |
| New-onset AF | 297 (23.6%) | 174 (29.8%) | 123 (18.3%) | 0.047 |
| Idiopathic AF | 301 (24%) | 110 (18.8%) | 191 (28.4%) | 0.039 |
| Paroxysmal AF | 417 (33%) | 152 (26%) | 265 (39%) | 0.03 |
| Persistent AF | 677 (54%) | 333 (57%) | 344 (51%) | <0.001 |
| Long-lasting persistent/permanent | 162 (13%) | 99 (17%) | 63 (10%) | <0.001 |
| Duration of AF (years) | 2 (0–5) | 1 (0–4) | 3 (1–5) | 0.01 |
| Number of arrhythmic episodes during the last year | 1 (1–3) | 1 (1–2) | 1 (1–4) | <0.01 |
| Number of hospitalizations for AF during the last year | 0 (0–1) | 1 (0–1) | 1 (1–2) | 0.252 |
| Number of antiarrhythmic drugs | 1 (0–2) | 1 (0–1) | 1 (1–2) | <0.01 |
| Amiodarone | 467 (37.2%) | 193 (33%) | 274 (40.8%) | 0.189 |
| SSS: brady–tachy form | 108 (8.5%) | 69 (11.8%) | 39 (5.8%) | 0.06 |
| Cardiac pacing | 134 (10.7%) | 68 (11.6%) | 66 (9.8%) | 0.741 |
| Previous catheter ablation | 116 (9.2%) | 24 (4.1%) | 92 (13.7%) | <0.01 |
| Thrombo-embolic risk ≥1 | 1053 (83.8%) | 502 (86%) | 551(82%) | 0.210 |
| OAT contraindications | 36 (2.9%) | 20 (3.4%) | 16 (2.4%) | 0.268 |
| Symptoms correlated to AF | 914 (72.8%) | 384 (65.8%) | 530 (78.9%) | 0.006 |
| Significant symptom | 654 (52.1%) | 244 (41.8%) | 410 (61%) | 0.01 |
| QoL impairment | 406 (32.3%) | 159 (27.2%) | 247 (36.8%) | 0.232 |
| EF deterioration due to AF | 144 (11.5%) | 74 (12.7%) | 70 (10.4%) | 0.373 |
| Refractoriness to medical therapy | 492 (39.2%) | 136 (23.3%) | 356 (53%) | <0.01 |
AF, atrial fibrillation; SSS, sick sinus syndrome; OAT, oral anticoagulant therapy; QoL, quality of life; EF, ejection fraction.
| Variables . | Total . | Non-ablation centres ( n = 23) . | Ablation centres ( n = 20) . | P . |
|---|---|---|---|---|
| Patient number, total | 1256 | 584 | 672 | |
| Outpatients | 694 (55.3%) | 300 (51.4%) | 394 (58.6%) | 0.323 |
| Age, years | 68 ± 12 | 69 ± 12 | 66 ± 11 | <0.01 |
| Males | 672 (53.5%) | 338 (57.9%) | 424 (63.1%) | 0.058 |
| Ejection fraction, % | 54 ± 10 | 54 ± 9 | 54 ± 10 | 0.793 |
| Left atrium diameter, mm | 4.6 ± 0.7 | 4.6 ± 0.7 | 4.6 ± 0.8 | 0.6 |
| Hypertension | 487 (38%) | 246 (42%) | 241 (36%) | <0.01 |
| Structural heart disease | 468 (37%) | 226 (38%) | 242 (36%) | 0.113 |
| Ischaemic | 147 | 82 | 65 | 0.07 |
| Hypertensive | 37 | 19 | 18 | 0.811 |
| Dilated | 96 | 34 | 62 | <0.01 |
| Valvular | 151 | 79 | 72 | 0.37 |
| Other | 37 | 12 | 25 | 0.05 |
| New-onset AF | 297 (23.6%) | 174 (29.8%) | 123 (18.3%) | 0.047 |
| Idiopathic AF | 301 (24%) | 110 (18.8%) | 191 (28.4%) | 0.039 |
| Paroxysmal AF | 417 (33%) | 152 (26%) | 265 (39%) | 0.03 |
| Persistent AF | 677 (54%) | 333 (57%) | 344 (51%) | <0.001 |
| Long-lasting persistent/permanent | 162 (13%) | 99 (17%) | 63 (10%) | <0.001 |
| Duration of AF (years) | 2 (0–5) | 1 (0–4) | 3 (1–5) | 0.01 |
| Number of arrhythmic episodes during the last year | 1 (1–3) | 1 (1–2) | 1 (1–4) | <0.01 |
| Number of hospitalizations for AF during the last year | 0 (0–1) | 1 (0–1) | 1 (1–2) | 0.252 |
| Number of antiarrhythmic drugs | 1 (0–2) | 1 (0–1) | 1 (1–2) | <0.01 |
| Amiodarone | 467 (37.2%) | 193 (33%) | 274 (40.8%) | 0.189 |
| SSS: brady–tachy form | 108 (8.5%) | 69 (11.8%) | 39 (5.8%) | 0.06 |
| Cardiac pacing | 134 (10.7%) | 68 (11.6%) | 66 (9.8%) | 0.741 |
| Previous catheter ablation | 116 (9.2%) | 24 (4.1%) | 92 (13.7%) | <0.01 |
| Thrombo-embolic risk ≥1 | 1053 (83.8%) | 502 (86%) | 551(82%) | 0.210 |
| OAT contraindications | 36 (2.9%) | 20 (3.4%) | 16 (2.4%) | 0.268 |
| Symptoms correlated to AF | 914 (72.8%) | 384 (65.8%) | 530 (78.9%) | 0.006 |
| Significant symptom | 654 (52.1%) | 244 (41.8%) | 410 (61%) | 0.01 |
| QoL impairment | 406 (32.3%) | 159 (27.2%) | 247 (36.8%) | 0.232 |
| EF deterioration due to AF | 144 (11.5%) | 74 (12.7%) | 70 (10.4%) | 0.373 |
| Refractoriness to medical therapy | 492 (39.2%) | 136 (23.3%) | 356 (53%) | <0.01 |
| Variables . | Total . | Non-ablation centres ( n = 23) . | Ablation centres ( n = 20) . | P . |
|---|---|---|---|---|
| Patient number, total | 1256 | 584 | 672 | |
| Outpatients | 694 (55.3%) | 300 (51.4%) | 394 (58.6%) | 0.323 |
| Age, years | 68 ± 12 | 69 ± 12 | 66 ± 11 | <0.01 |
| Males | 672 (53.5%) | 338 (57.9%) | 424 (63.1%) | 0.058 |
| Ejection fraction, % | 54 ± 10 | 54 ± 9 | 54 ± 10 | 0.793 |
| Left atrium diameter, mm | 4.6 ± 0.7 | 4.6 ± 0.7 | 4.6 ± 0.8 | 0.6 |
| Hypertension | 487 (38%) | 246 (42%) | 241 (36%) | <0.01 |
| Structural heart disease | 468 (37%) | 226 (38%) | 242 (36%) | 0.113 |
| Ischaemic | 147 | 82 | 65 | 0.07 |
| Hypertensive | 37 | 19 | 18 | 0.811 |
| Dilated | 96 | 34 | 62 | <0.01 |
| Valvular | 151 | 79 | 72 | 0.37 |
| Other | 37 | 12 | 25 | 0.05 |
| New-onset AF | 297 (23.6%) | 174 (29.8%) | 123 (18.3%) | 0.047 |
| Idiopathic AF | 301 (24%) | 110 (18.8%) | 191 (28.4%) | 0.039 |
| Paroxysmal AF | 417 (33%) | 152 (26%) | 265 (39%) | 0.03 |
| Persistent AF | 677 (54%) | 333 (57%) | 344 (51%) | <0.001 |
| Long-lasting persistent/permanent | 162 (13%) | 99 (17%) | 63 (10%) | <0.001 |
| Duration of AF (years) | 2 (0–5) | 1 (0–4) | 3 (1–5) | 0.01 |
| Number of arrhythmic episodes during the last year | 1 (1–3) | 1 (1–2) | 1 (1–4) | <0.01 |
| Number of hospitalizations for AF during the last year | 0 (0–1) | 1 (0–1) | 1 (1–2) | 0.252 |
| Number of antiarrhythmic drugs | 1 (0–2) | 1 (0–1) | 1 (1–2) | <0.01 |
| Amiodarone | 467 (37.2%) | 193 (33%) | 274 (40.8%) | 0.189 |
| SSS: brady–tachy form | 108 (8.5%) | 69 (11.8%) | 39 (5.8%) | 0.06 |
| Cardiac pacing | 134 (10.7%) | 68 (11.6%) | 66 (9.8%) | 0.741 |
| Previous catheter ablation | 116 (9.2%) | 24 (4.1%) | 92 (13.7%) | <0.01 |
| Thrombo-embolic risk ≥1 | 1053 (83.8%) | 502 (86%) | 551(82%) | 0.210 |
| OAT contraindications | 36 (2.9%) | 20 (3.4%) | 16 (2.4%) | 0.268 |
| Symptoms correlated to AF | 914 (72.8%) | 384 (65.8%) | 530 (78.9%) | 0.006 |
| Significant symptom | 654 (52.1%) | 244 (41.8%) | 410 (61%) | 0.01 |
| QoL impairment | 406 (32.3%) | 159 (27.2%) | 247 (36.8%) | 0.232 |
| EF deterioration due to AF | 144 (11.5%) | 74 (12.7%) | 70 (10.4%) | 0.373 |
| Refractoriness to medical therapy | 492 (39.2%) | 136 (23.3%) | 356 (53%) | <0.01 |
AF, atrial fibrillation; SSS, sick sinus syndrome; OAT, oral anticoagulant therapy; QoL, quality of life; EF, ejection fraction.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
